

Malta Medicines Authority

Report No: **MT/005NCR/2024**

STATEMENT OF NON-COMPLIANCE WITH GMP

Exchange of information between National Competent Authorities (NCAs) of the EEA following the discovery of serious GMP non-compliance at a manufacturer¹

Part 1

Issued following an inspection in accordance with
Art. 111(7) of Directive 2001/83/EC as amended

The competent authority of Malta confirms the following:

The manufacturer: **Maxheal Pharmaceuticals (India) Limited**

Site address: **Plot No 95/6 Midc Satpur, Nashik, 422007, India**

OMS Organisation Id. / OMS Location Id.: **ORG-100039339 / LOC-100061928**

Other

(Human) Directive (EU) 2017/1572

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2024-10-08**, it is considered that **it does not comply with the Good Manufacturing Practice** requirements referred to in

•

Note to receiving authorities: Please contact the issuing authority within 20 working days in case there are critical(2) medicinal products potentially affected by this statement.

Manufacturing Authorisation Holders directly affected by this statement have failed to comply with their obligations under Art. 46 of Directive 2001/83/EC or Art. 93(1)(j) to (l) of Regulation (EU) 2019/6 and as a consequence the Qualified Person referred to in Art. 48 of Directive 2001/83/EC and Art. 97(1) of Regulation (EU) 2019/6 is unable to perform the batch certification referred to in Art. 51 of Directive 2001/83/EC and Art. 97 (6) and (7) of Regulation (EU) 2019/6.

In exceptional circumstances there may be no objection to the Qualified Person certifying affected batches thereby allowing their release provided all of the following conditions are fulfilled:

1. Batch certification is performed in order to maintain supply of critical medicinal products only.
2. A documented risk assessment has been performed by, or on behalf of, the Qualified Person and additional actions have been implemented by the manufacturing and/or batch release site to mitigate the risks posed by the non-compliance. Note: Repeated testing alone is not normally sufficient risk mitigation but, together with other actions, can form part of a strategy commensurate with the nature and the level of risk.
3. A thorough risk-benefit evaluation has been performed for the acceptance of risk and a report prepared that takes full account of the nature of the non-compliance with the involvement of:
 - The Manufacturing Authorisation Holder and the Qualified Person of the site responsible for batch certification.

- The manufacturing site subject to this Statement of Non-Compliance, if different from the above.
- The relevant Marketing Authorisation Holder(s).

The report has been shared with the National Competent Authorities of the countries in which distribution of the affected batches is anticipated and that any comments from those authorities have been taken into account.

4. Written confirmation has been obtained from the National Competent Authorities in whose territories the affected batches are intended to be distributed that the product is considered critical on its territory, and that there is no objection to distribution.
5. The Supervisory Authority has been informed, if different from the above, and it has not suspended or revoked the relevant Manufacturing Authorisation.
6. The affected Marketing Authorisations have not been revoked or suspended.
7. Any further conditions imposed by the Supervisory Authority and other involved National Competent Authorities are met.

¹The statement of non-compliance referred to in paragraph 111(7) of Directive 2001/83/EC and Art. 94(2) of Regulation (EU) 2019/6, as amended, is also applicable to importers.

²See Appendix 3 of the relevant procedure in the Compilation of Union Procedures.

Part 2

Human Medicinal Products	
1 NON-COMPLIANT MANUFACTURING OPERATIONS	
Include total and partial manufacturing (including various processes of dividing up, packaging or presentation), batch release and certification, storage and distribution of specified dosage forms unless informed to the contrary;	
1.2	Non-sterile products
	<i>1.2.1 Non-sterile products (processing operations for the following dosage forms)</i> 1.2.1.1 Capsules, hard shell
1.5	Packaging
	<i>1.5.1 Primary Packaging</i> 1.5.1.1 Capsules, hard shell
1.6	Quality control testing
	<i>1.6.2 Microbiological: non-sterility</i> <i>1.6.3 Chemical/Physical</i>

Part 3

1.Nature of non-compliance:
Following an onsite inspection carried out between 4th to 8th October 2024 at Maxheal Pharmaceuticals (India) Ltd, the inspection team registered 2 critical and 5 major deficiencies, amongst a number of others, namely: data integrity issues, failures in cross-contamination containment measures, ineffective implementation of an adequate and good documentation system, systematic absence of training throughout the company, inadequate qualification and approval of suppliers, and failures in artwork control and in encapsulation operations, amongst others.
Action taken/proposed by the NCA
Suspension of the marketing authorisation(s) Member States should consider refraining from initiating or authorizing marketing authorization applications that list this site as a finished product manufacturing site until the recommended non-compliance statement is issued and remains in place.
Others Withdrawal of MT/032HM/2022
Additional comments A draft supervisory risk assessment was circulated through the rapid alert network for any comments by NCAs with a deadline for responses set to the 11th of November 2024 (1 week from date of issue). No replies were received as of 12th November 2024, and therefore the draft supervisory risk assessment and non-compliance statement along with their recommendations will be implemented.

2024-11-12

Name and signature of the authorised person of the
Competent Authority of Malta

Confidential
Malta Medicines Authority
Tel: ***Confidential***
Fax: ***Confidential***